Skip to content

Combined detection of epigenetics and metabonomics for the differential diagnosis of benign and malignant pulmonary nodules

Combined detection of epigenetics and metabonomics for the differential diagnosis of benign and malignant pulmonary nodules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083876
Enrollment
Unknown
Registered
2024-05-06
Start date
2024-05-06
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:Pathological results of biopsy or surgery
Index test:Combined methylation and metabolomics detection

Sponsors

Zhongshan hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: a)CT findings in patients with pulmonary nodules (6-30 mm), patients requiring pathological diagnosis, or normal people with no abnormalities in the lung CT examination . b) Sign informed consent c) Age 18-80

Exclusion criteria

Exclusion criteria: a) Previous history of malignant tumor b) Unwillingness to sign informed consent c) Pregnant persons

Design outcomes

Primary

MeasureTime frame
The performance of blood methylation detection, the performance of metabolomics detection, the performance of blood methylation index combined with metabolomics multi-omics detection for the identification of benign and malignant pulmonary nodules, and combined with LDCT and other imaging techniques to improve the accuracy of benign and malignant pulmonary nodules;

Secondary

MeasureTime frame
Screening of metabolite targets and methylation targets in Chinese lung cancer population; Relationship between metabolite targets and methylation targets and pathological classification and staging of lung cancer;

Countries

China

Contacts

Public ContactYong Zhang

Zhongshan hospital, Fudan University

zhangyong983016@hotmail.com+86 150 0022 9853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026